| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.90B | 1.48B | 1.31B | 1.38B | 1.98B |
| Gross Profit | 1.78B | 1.48B | 1.30B | 1.37B | 1.97B |
| EBITDA | 412.92M | 245.48M | 159.96M | 165.38M | 484.22M |
| Net Income | 281.33M | 181.11M | 85.49M | 110.67M | 278.51M |
Balance Sheet | |||||
| Total Assets | 0.00 | 2.26B | 2.14B | 2.18B | 2.57B |
| Cash, Cash Equivalents and Short-Term Investments | 0.00 | 482.83M | 383.10M | 365.62M | 970.97M |
| Total Debt | 0.00 | 98.82M | 164.16M | 234.77M | 214.63M |
| Total Liabilities | -1.46B | 840.16M | 841.51M | 927.53M | 1.34B |
| Stockholders Equity | 1.46B | 1.23B | 1.09B | 1.05B | 1.06B |
Cash Flow | |||||
| Free Cash Flow | 697.53M | 297.76M | 265.58M | -255.51M | 686.51M |
| Operating Cash Flow | 732.19M | 313.25M | 275.63M | -224.91M | 707.09M |
| Investing Cash Flow | -178.01M | -31.77M | -10.05M | -127.10M | -20.58M |
| Financing Cash Flow | -229.94M | -180.61M | -249.59M | -250.06M | -223.12M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $5.42B | 18.68 | 21.65% | 1.63% | 12.77% | 36.43% | |
71 Outperform | $4.80B | 20.18 | 46.14% | 3.69% | 51.19% | 456.59% | |
71 Outperform | $7.19B | 22.10 | 72.74% | 0.58% | 23.16% | 64.04% | |
69 Neutral | $11.70B | 18.91 | 11.72% | 1.43% | 7.54% | 2.73% | |
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% | |
60 Neutral | $4.77B | 21.36 | 30.59% | 4.06% | 1.58% | 1.93% | |
57 Neutral | $9.41B | 15.68 | 6.13% | 2.52% | -5.41% | 25.28% |
On February 6, 2026, Piper Sandler announced that its board of directors approved a four-for-one forward stock split of the company’s common stock, to be implemented by increasing the number of authorized shares through an amendment to its certificate of incorporation. The amendment is expected to take effect at 4:30 p.m. Eastern Time on March 23, 2026, with each existing share converting into four shares, and the company’s common stock beginning to trade on a split-adjusted basis on March 24, 2026, a move that could enhance liquidity and broaden the shareholder base.
The most recent analyst rating on (PIPR) stock is a Hold with a $354.00 price target. To see the full list of analyst forecasts on Piper Sandler stock, see the PIPR Stock Forecast page.
Effective February 4, 2026, Piper Sandler Companies expanded its board of directors from nine to ten members and elected Stuart M. Essig as a director for an initial term ending at the firm’s 2026 annual meeting of shareholders, also appointing him to the Audit Committee. Essig, the longtime former chief executive and current chairman of Integra LifeSciences Corporation and a director at IDEXX Laboratories, will join Piper Sandler’s 2026 non-employee director compensation program, receiving a pro-rated cash retainer and equity awards, and the company noted there are no special arrangements or related-party transactions connected to his appointment, underscoring standard governance practices around the board refresh announced on February 4, 2026.
The most recent analyst rating on (PIPR) stock is a Hold with a $384.00 price target. To see the full list of analyst forecasts on Piper Sandler stock, see the PIPR Stock Forecast page.